The present invention pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.本發明係關於針對癌症抗原MUC1之新穎抗體。特定而言,經由刪除於已知抗MUC1抗體之CDR-H2中之糖化位點來獲得具有經改良抗原結合的抗體。